Moucellion Therapeutics
- Biotech or pharma, therapeutic R&D
Moucellion Therapeutics Co., Ltd. is a biotech company specializing in the development of innovative therapeutics, including induced pluripotent stem cell (iPSC)-based cell therapy and adeno-associated virus (AAV)-mediated gene therapy, to treat ophthalmic diseases characterized by a large patient population, unmet medical needs, and the absence of current effective treatment options.
Our key pipelines include autologous and universal iPSC-derived Retina Pigment Epithelial (RPE) cells to treat AMD. Encouragingly, we are advancing our autologous iPSC-RPE cells into clinical trial in China. In addition, we are also developing ABCA4 gene therapy via a dual AAV system for Stargardt’s Disease.
Address
BeijingBeijing
China
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}